2016
BCOR regulates myeloid cell proliferation and differentiation
Cao Q, Gearhart M, Gery S, Shojaee S, Yang H, Sun H, Lin D, Bai J, Mead M, Zhao Z, Chen Q, Chien W, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell V, Koeffler H. BCOR regulates myeloid cell proliferation and differentiation. Leukemia 2016, 30: 1155-1165. PMID: 26847029, PMCID: PMC5131645, DOI: 10.1038/leu.2016.2.Peer-Reviewed Original ResearchConceptsMyeloid cell proliferationHox genesCell proliferationFunction mutationsUbiquitin ligase subunitRNA expression profilingPolycomb groupEnhanced cell proliferationOverexpression allelesHOXA genesExpression profilingGene expressionConditional lossMyeloid differentiationMurine cellsFamily complexesNormal hematopoiesisGenesBone marrow cellsBCOR expressionProtein levelsMechanistic explanationDifferentiation rateAML patient samplesMutations
2012
BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes
Cao Q, Gery S, Shojaee S, Gearhart M, Bardwell V, Muschen M, Koeffler H. BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes. Blood 2012, 120: 3445. DOI: 10.1182/blood.v120.21.3445.3445.Peer-Reviewed Original ResearchHox genesMyeloid cell differentiationCell differentiationCell linesIndividual Hox genesNormal hematopoiesisEssential developmental regulatorsStem cell stateOculofaciocardiodental syndromeEarly embryonic developmentCell growth controlStem cell functionTranscriptional repressive complexDownstream target genesTumor suppressor proteinGene expression profilesMesenchymal stem cell functionImmature hematopoietic cellsDevelopmental regulatorsPolycomb groupRepressive complexesHuman leukemic cell linesMost cell linesEmbryonic developmentSuppressor protein
2010
WNT/β-Catenin Signaling in Leukemia
Müschen M. WNT/β-Catenin Signaling in Leukemia. 2010, 129-142. DOI: 10.1007/978-1-4419-8023-6_6.Peer-Reviewed Original ResearchWnt/β-catenin signalingΒ-catenin signalingLeukemia stem cellsLeukemia-initiating cellsStem cellsRelapse of leukemiaMajor clinical problemWnt/β-cateninNovel therapy approachesActive Wnt/β-catenin signalingNormal hematopoiesisTreatment of leukemiaLeukemic cloneClinical problemLeukemia subtypesLeukemiaHematopoietic stem cellsNatural historyDrug resistanceMalignant outgrowthMultiple hematopoietic lineagesProgenitor cellsΒ-cateninTherapy approachesMyeloid progenitors
2009
Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia.
Jiang E, Park E, Scharman C, Hsieh Y, Kadavallore A, Nguyen C, Zhao Y, McMillan M, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia. Blood 2009, 114: 3072. DOI: 10.1182/blood.v114.22.3072.3072.Peer-Reviewed Original ResearchMedian survival timeAcute lymphoblastic leukemiaWhite blood cellsICG-001Control groupBlood cellsStandard chemotherapyRed blood cellsPeripheral bloodLymphoblastic leukemiaSmall molecule inhibitor ICG-001B-cell acute lymphoblastic leukemiaDrug resistanceCBP/β-cateninNormal hematopoiesisPromising therapeutic principleNormal white blood cellsConventional drug treatmentLeukemia cellsPrior intravenous injectionEnd of treatmentNovel therapeutic optionsNormal weight gainNew treatment modalitiesSubcutaneous osmotic pumps